Increased treatment of metastatic castration resistant prostate cancer (mCRPC) with second-generation 25 anti-androgen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate 26 cancer (AVPC) tumors that have lost androgen receptor (AR) signaling. AVPC tumors may also express 27 neuroendocrine markers, termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests 28 kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed 29 global phosphoproteomics comparing AR-negative to AR-positive prostate cancer cell lines and identified 30 multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-negative cell 31 lines. Clinical NEPC and NEPC patient derived xenografts displayed upregulated RET transcript and RET 32 pathway activity. Pharmacologically inhibiting RET kinase in NEPC models dramatically reduced tumor 33 growth and cell viability in mouse and human NEPC models. Our results suggest that targeting RET in NEPC 34 tumors with high RET expression and may be a novel treatment option. 35 36 Statement of Significance: 37 There are limited treatment options for patients with metastatic aggressive variant prostate cancer and 38 none are curative. Here we identified aberrantly activated RET kinase signaling in multiple models of 39 NEPC. Inhibiting RET restricted tumor growth, providing a novel approach for treating NEPC. 40 41 42
Introduction 43
Second-generation ADT, such as abiraterone acetate and enzalutamide, have provided much 44 needed life-extending therapies for recurrent or mCRPC patients. However, the utilization of these more 45 effective ADT therapies has coincided with an increase in the development of AVPC (1). This subset of 46 mCRPC is characterized by poor prognosis and loss of AR signaling (2). The absence of AR signaling in AVPC 47 renders the existing hormone targeting treatments ineffective and remaining approved therapies, 48
including platinum-based chemotherapy, offer only limited therapeutic benefits (3). A subset of AVPC 49 tumors are classified as NEPC because they express neuroendocrine genes which are not typically 50 expressed in prostate adenocarcinoma (AdCa) . Recent work has implicated the loss of RB1 and TP53 51 mutations as key alterations in the development of NEPC, and inhibition of kinases such as Aurora A kinase 52 (AURKA), MAPK, or FGFR could provide therapeutic opportunities if selected in the right patient subsets 53 (1, (4) (5) (6) . Even with these new developments, there still remains a critical need to understand the molecular 54 characteristics and kinase signaling pathways of NEPC tumors to identify and validate effective treatment 55 options. 56
Receptor tyrosine kinases link the extracellular environment to intracellular responses through 57 multiple signaling cascades. These signaling cascades regulate numerous pathways that are frequently 58 altered in transformed cells, including cell growth, metabolism, proliferation, differentiation, invasion, 59 motility, and cell death (7) . RET is a receptor tyrosine kinase that is essential for neural crest development 60 and is frequently mutated or translocated in subsets of endocrine tumors such as multiple endocrine 61 neoplasia 2 (MEN2) and papillary thyroid carcinomas, respectively (8). RET can be therapeutically targeted 62 with some success in these tumor types. Recently, RET kinase was identified to be tyrosine phosphorylated 63 in a CRPC patient with small cell neuroendocrine pathology (9) and as an enriched cell surface marker in 64 NEPC (10). Further, RET knockdown restricted invasion and proliferation of prostate adenocarcinoma in 65 vivo (11). However, it remains unclear whether RET kinase contributes to the growth of NEPC tumors and 66 whether RET inhibition could be exploited as a therapeutic target in this setting. 67
Here, we evaluated the phosphoproteome of multiple AR negative and AdCa prostate cancer cell 68 lines to identify altered kinase signaling pathways unique to AR negative prostate cancers. Several 69 downstream signaling networks of RET kinase, and RET kinase itself, were enriched and activated in the 70 AR negative cell lines when compared to AdCa cell lines. Additionally, RET kinase was overexpressed in 71 NEPC tumors in multiple clinical datasets. We evaluated the ability of a novel RET pathway inhibitor, AD80, 72 to block cell growth and reduce cell viability in multiple prostate cancer cell lines and observed that it was 73 more potent than current RET-directed FDA approved therapies, cabozantinib and vandetanib (12, 13) . 74
Finally, we found that AD80 was effective in blocking tumor growth and reducing tumor viability of NEPC 75 xenograft tumor models as well as organoid models. These results indicate that RET kinase is active in 76 NEPC, contributes to the survival of NEPC tumors, and inhibiting RET induces cell death in neuroendocrine 77 prostate cancer cells that are resistant to current hormonal therapies. These results ultimately nominate 78 RET as a key candidate to test further in the development and effective treatment of NEPC. 79 80
Results

81
AR negative cell lines have altered phosphotyrosine and phosphoserine/threonine kinase signaling 82 pathways. To identify the unique kinase signaling pathways required for growth and proliferation of AR 83 negative, we performed phosphoproteomic profiling to compare androgen responsive, AR-full length 84 positive, AdCa cell lines (LNCaP, VCaP, C4-2, and 22Rv1), to AR low/null cell lines that are resistant to ADT 85 and harbor mutations commonly found in NEPC tumor samples (DU145, PC3, NCI-H660, cMyc/myrAKT, 86 LASCPC-01, EF-1, and PARCB-1,-2,-3, and -5) ( Supplemental Table 1 ). Supervised hierarchical clustering 87 between the AdCa and AR negative groups revealed distinct patterns in phosphoserine/threonine (pS/T) 88 and phosphotyrosine (pY) ( Figure 1A and 1B, respectively and Supplemental Tables 2 and 3) . Kinase 89 substrate enrichment analysis (KSEA) identified AURKA as the most highly enriched pS/T kinase (Figure 90 1C) that has been previously reported to be significantly upregulated in NEPC (4). Interestingly, among 91 the tyrosine kinases, RET kinase was also significantly enriched ( Figure 1D ), suggesting that RET kinase is 92 activated in AVPC cell lines (full pS/T and pY KSEA results are in Supplemental Tables 4 and 5, respectively). 93
We confirmed RET protein to be upregulated in the NEPC subset of AVPC cell lines compared to AdCa and 94 confirmed the loss of full length AR (Supplemental Figure 1 ). Further investigation into the RET pathway 95 via our cell line-derived and our previously published mCRPC rapid autopsy phosphoproteomic datasets 96 (9) (expanded phosphoproteome data set in Supplemental Table 6 , see methods) identified hyper-97 phosphorylation and, in some cases, activation, of several RET pathway targets including MAPK, AKT, and 98 STAT3 ( Figure 1E , 1F), further confirming RET pathway activity in AVPC cell lines and tumors. 99 100 RET kinase expression is upregulated in patients with neuroendocrine prostate cancer. We took 101 advantage of several clinical prostate cancer gene expression datasets to determine whether RET kinase 102 was overexpressed along with known markers of NEPC. Analysis of the University of Washington rapid 103 autopsy dataset (14) which contains multiple metastatic tumors from CRPC patients revealed that the 104 NEPC (AR negative, neuroendocrine positive) subset had enrichment of RET kinase expression 105 concomitant with increased ASCL1 and chromogranin A (CHGA) and decreased AR, NKX3-1, and KLK3 106 expression ( Figure 2A ). Among patients with an AR-negative, NE-positive pathology, there was a strong 107 correlation between levels of RET and ASCL1, while there was no correlation in the other groups ( Figure  108 2B). Additional transcript datasets comparing metastatic NEPC to metastatic AdCa ( Figure 2C and 109 Supplemental Figure 2A ) (6, 15) or LuCaP neuroendocrine prostate cancer patient-derived xenografts 110 (PDXs) with AdCa PDXs ( Figure 2D ) (16) both showed similar trends of increased RET kinase expression 111 along with upregulation of CHGA and SYP in the NEPC samples. Transcripts from biopsies of progressive, 112 mCRPC samples that followed patients through disease progression revealed clusters of high RET and 113 ASCL1 expression with a strong downregulation of AR regulated genes (Supplemental Figure 2B ) (17). 114
Overall, these independent datasets demonstrate that RET kinase is overexpressed in clinical NEPC tumors 115 and support our cell line phosphoproteomic and KSEA analyses, suggesting enhanced RET activity and 116 nominating RET as a candidate therapeutic target for NEPC tumors. 117
118
AD80 reduces tumor growth in RET expression high NCI-H660 xenograft tumors by increasing cell death. 119
AD80 is a novel, more selective inhibitor of the RET pathway than previous multi tyrosine kinase inhibitors 120 such as cabozantinib or vandetanib (13). We found that the NEPC cell line, NCI-H660, was among the most 121 sensitive to AD80 treatment (Supplemental Figure 3 ) and expressed high levels of RET protein 122 (Supplemental Figure 1) . To test the effect of AD80 in an in vivo model system of NEPC, we generated NCI-123 H660 xenograft tumors in NOD-SCID mice. Once tumors reached 100-200 mm 3 , mice were randomized 124 and placed into one of three treatment groups: Control (DMSO), 20 mg/kg enzalutamide, or 10 mg/kg 125 AD80 ( Figure 3A ). Over the course of the 22-day treatment, AD80 treated tumors showed a significant 126 reduction in overall tumor volume ( Figure 3B ) without a significant effect on animal weight ( Figure 3C ). 127
This experiment was repeated in a second cohort of mice with 24 days of treatment and higher dose of 128 AD80 (20 mg/kg). The higher dose of AD80 was associated with increased toxicity, but showed similar 129 inhibition of tumor growth throughout the 24-day treatment (Supplemental Figure 4) . 130
Following treatment, the AD80 treated tumors appeared smaller and displayed less 131 vascularization ( Figure 3D and Supplemental Figure 4C ), suggesting that AD80 treatment restricted tumor 132 progression possibly via reduction of angiogenesis which has been reported in other neuroendocrine 133 tumor types treated with RET inhibitors (18). To interrogate the molecular characteristics of the different 134 treatments, the tumors were fixed and sectioned for staining. Sections angiogenesis, tumor sections from the xenograft tumors were stained with a CD31 antibody ( Figure 3E ). 138
The AD80 treated group had a statistically significant reduction in elongated CD31 positive cells compared 139 to the control or enzalutamide treated groups ( Figure 3G ). The reduction in CD31 staining was not 140 observed in the second cohort of mice, but the tumors were collected at a point when they were growing 141 at similar rate to the control group (Supplemental Figure 4A , D, and F). There was no difference in 142 proliferation as assayed by Ki67 staining among the treatment groups in either cohort of mice ( Figure 3E , 143 H, and Supplemental Figure 4D and G). However, TUNEL staining showed large regions of positive staining 144 the percentage of total tumor area that stained positive trended higher in the AD80 treated groups (Figure  145 3E, I and supplemental Figure 4D and H). Taken together, the staining suggests that AD80 treatment is 146 effective in limiting tumor growth by restricting angiogenesis and inducing death in neuroendocrine cells 147 with high RET expression. 148 149 AD80 induces cell death in NEPC organoid models. We next extended our AD80 treatment to a mouse 150 organoid model of NEPC (5). Tumors derived from the PTEN -/-Rb -/-(DKO) mice express higher levels of RET 151 mRNA than PTEN -/-(SKO) or wild type (WT) animals ( Figure 4A ) (5). Immunofluorescence staining also 152 confirmed an increase of RET kinase protein in the DKO organoids and low to absent RET kinase in the SKO 153 organoids ( Figure 4B ). The DKO organoids were resistant to enzalutamide treatment, mimicking the ADT 154 resistant characteristic of NEPC prostate cancer cells that express high levels of RET ( Figure 4C ). Treating 155 the DKO organoids with increasing concentrations of AD80 induced a dose-dependent increase in cell 156 death, as assayed by live-dead PI staining of the organoids with a calculated LD50 of 8.3µM for AD80 ( Figure  157 4D, E). High RET expressing NCI-H660 cells cultured as organoids showed a similar sensitivity to AD80 158 treatment (Supplemental Figure 5 ). Thus, inhibiting RET kinase with AD80 in an in vitro organoid system 159 of NEPC induced cell death and suggests that the specific population of patients that have high RET 160 expression, are refractory to ADT, and have few remaining therapeutic options, may benefit from RET 161 kinase inhibitor therapies. 162 163
Discussion 164
Increasing evidence points to the activation of kinase pathways as possible key mechanisms that 165 bypass AR-targeted therapies and allow the tumors to continue to survive such a harsh therapeutic 166 environment (1, 4, 19, 20) . Utilizing phosphoproteomics, we showed that AR-negative cell lines have 167 altered kinase signaling pathways compared to AR-driven adenocarcinomas, which includes activation of 168 RET kinase. Multiple proteins downstream of the RET kinase pathway were phosphorylated on activating 169 residues in both the cell line and in mCRPC autopsy patient samples. RET mutations or activating 170 rearrangements are drivers of tumor development and growth in MEN2, medullary thyroid cancer and 171 small cell and non-small cell lung cancers, and drugs targeting RET can extend survival of these patients 172 (21) (22) (23) . Cabozantinib, which inhibits RET kinase and other receptor tyrosine kinases including VEGR1/2, 173 has extended survival in certain cancers with activating RET mutations (24, 25) . In prostate cancer 174 cabozantinib showed promising phase II clinical trials but failed to meet the endpoint criteria in phase III 175 trials (NCT00940225). However, this was tested in a non-stratified patient population and did not focus 176 on NEPC (26). A retrospective evaluation of post-docetaxel patients with CRPC in the COMET-1 and 177 COMET-2 phase III clinical trials where cabozantinib was compared with prednisone and prednisone plus 178 mitoxantrone suggest that a sub population may benefit from cabozantinib treatment, highlighting the 179 importance of molecular stratification of patients for individualized treatments (27) (28) (29) . Recently, RET 180 knockdown in a prostate AdCa cell line, LNCaP, was reported to restrict tumor growth, but it remains 181 unclear if and how RET contributes to tumor progression in NEPC (11). 182
We found that overall RET expression in prostate cancer patient samples is highly variable, but 183 that RET kinase expression correlated very strongly with NEPC. Although, there were examples of 184 metastatic and treatment induced NEPC tumors (based on molecular and pathological features) that lack 185 RET gene expression and inversely there were also patients classified as AR-positive adenocarcinomas 186 that had high levels of RET gene expression, but low gene expression of other neuroendocrine markers 187 ( Figure 2A and Supplemental Figure 2A ). It is important to note that the transition from AdCa to NEPC may 188 be dynamic (5) and RET expression in AR positive tumors may suggest that these tumors are either a 189 heterogeneous phenotype or are transitioning from AdCa to NEPC. Currently, little is known about the 190 regulation of RET gene expression in prostate cancer. Several key epigenetic regulators (such as CBX2, 191 EZH2, BRN2, and SOX2) have been identified as possible modulators that can switch tumors between an 192 AdCa and NEPC state (5, (30) (31) (32) . Alterations in DNA methylation or transcriptional regulation resulting from 193 the loss of proteins such as Rb may further alter RET expression and activity. Therefore, it remains how 194 robust RET expression is gained during the transition from mCRPC to a NEPC phenotype. In small cell lung 195 cancer, ASCL1 was shown to induce RET gene expression and this mechanism of regulation may hold true 196 in NEPC, but has not been validated (33). 197 Regardless of the dynamics of RET expression in disease progression, we showed that the RET 198 kinase pathway inhibitor AD80 effectively restricted growth in the Rb/PTEN knockout organoids and the 199 NCI-H660 cell line and organoids in vitro, as well as NCI-H660 tumors in vivo. Inhibiting RET kinase induced 200 cell death suggesting that RET kinase signaling may be important for tumor survival. In order to identify 201 patients that could benefit from treatment including RET inhibition, it will be important to generate assays 202 or validate markers of RET activity in NEPC. Pathology, loss of AR signaling, or expression of 203 neuroendocrine genes are not sufficient alone to identify all patients with high levels of RET expression 204 that may benefit from RET targeted therapies. Moving forward, it will be important to identify the subset 205 of patients that would benefit from inhibition of RET kinase. Development of biomarkers for 206 transcriptional activators, RET protein, or markers of RET activity will enable pre-selection of individuals 207 who would benefit from RET inhibitors. Understanding the regulation of RET gene expression, correlation 208 of RET expression and activity and disease progression, as well as the contribution of RET kinase to mCRPC 209 tumor progression could inform better treatment strategies. 210 211
Material and Methods 212
Phosphoproteomics of Prostate Cancer Cell Lines 213
Cultured prostate cancer cells were scraped, pelleted, and snap frozen. Phosphopeptide 214 enrichment and trypsin digestion were performed as previously described (34) Supplemental Table 6 . 232
Phosphoproteome MS data analysis was performed as previously described (20) . For supervised 233 clustering, pY and pS/T data were filtered using a 4-fold change cutoff comparing NEPC vs AdCa from the original excel tables (See Supplemental Tables 2 and 3 and 1% penicillin-streptomycin (Life Technologies). NCI-H660 cells were grown in RPMI-HITES medium: 252 RPMI, 5% FBS, 10 nM hydrocortisone (Sigma), 10 nM beta-estradiol (Sigma), insulin-transferrin-selenium 253 (Life Technologies), 1% penicillin-streptomycin, and Glutamax (Life Technologies). LASCPC-01, 254 cMyc/myrAKT, PARCB2 and PARCB5, and EF1 cell lines were obtained from Dr. Owen Witte at UCLA and 255 cultured as described (10, 40, 41) . H660 organoids were cultured as described in (42). LNCaP95 cells were 256 cultured in RPMI 1640 with no phenol red supplemented with 10% charcoal-stripped serum, Glutamax, 257 and 1% penicillin-streptomycin. Mouse organoids were established by enzymatic digestion of GEMM 258 primary prostate tumor tissue in 5 mg/ml Collagenase type II (Gibco) in adDMEM/F12 (Gibco) media with 259 10 µM Y-27632 dihydrochloride (Tocris Bioscience). Digested cells were seeded into 100% Matrigel and 260 cultured as described by Drost et. al 2016. NCI-H660 organoids were seeded into Prostate 18 QGel 3D 261 Matrix (QGel) according to manufacturer's instructions and cultured in RPMI-HITES media with B27 262 supplement (Gibco), 1.25 mM N-acetylcysteine (Sigma), 5 ng/mL EGF (PeproTech), 500 nM A83-01 (Tocris 263 Bioscience), 5 ng/mL FGF2 (PeproTech), 10 ng/mL FGF10 (PeproTech), 10 mM Nicotinamide (Sigma), and 264 1 μM Prostaglandin E2 (Tocris Bioscience). Culture media was replenished every 4 days and organoids 265 were passaged by sequential digestion in 1 mg/mL Dispase II (Gibco) followed by TrypLE Express (Gibco) and mechanical disruption through a needle to dissociate to single cells before re-suspension as a 3D 267 culture. All cell lines were grown and maintained in a humidified incubator at 37°C and 5% CO2. 268 269 Antibodies 270
The following antibodies were used for IHC and IF: RET (Cell Signaling Technology, E1N8X, IF: 271 1:100 IHC 1:500), CD31 (Cell Signaling Technology, D8V9E, 1:100), and Ki67 (Cell Signaling Technology, 272 D2H10 1:400). 273
274
In vivo study 275
Experiments were carried out on 8 week old male NOD-SCID mice in accordance with IACUC 276 approved protocols. Xenografts were generated via subcutaneous injection of 1x10 6 NCI-H660 cells per 277 animal mixed at a 1:1 ratio with Corning Matrigel Matrix into the right flank. Tumors were allowed to grow 278 to approximately 100-200mm 3 before mice were randomly allocated into vehicle (5% DMSO), ENZA 279 (20mg/kg/day), and AD80 (10 mg/kg/day or 20mg/kg/day) treatment groups. Treatment proceeded once 280 daily, 5 days a week for 22 days by oral gavage. Tumor volume and animal weight were measured every 281 two days. Tumors volume was measured by caliper and expressed in mm 3 (Tumor Volume = 0.5 a × b 2 , 282 where a and b represents long and short diameter respectively). 283
284
Immunohistochemistry 285
Xenograft tumors were formalin fixed paraffin embedded and sectioned following standard 286 procedure. To stain, sections were deparaffinized by baking at 65°C for one hour and hydrated with 287 sequential washes in xylenes, 100% ethanol, 95% ethanol, 70% ethanol and 1xPBS, prior to citrate buffer 288 pH 6.0 antigen retrieval. To stain, tissues were washed with 0.1%TBST, blocked with 2.5% normal horse 289 serum for one hour at room temperature before incubating in primary antibody overnight at 4°C in a 290 humidified slide box. Slides were washed with 0.1%TBST and incubated in HRP-conjugated secondary 291 antibody (Vector Laboratories, MP-7500-15) for one hour at room temperature and developed using a 292 DAB peroxidase substrate kit (Vector Laboratories, NC9567138). Reaction was stopped with water before 293 proceeding to counterstaining with hematoxylin for one minute. Slides were de-stained in tap water, 294 dehydrated with ethanol and xylenes and mounted. 295 Tumor sections were imaged on a Zeiss Axiovert A2. Average RET or KI67 staining was determined 306 by color deconvolution followed by measurement of the mean gray value in the DAB channel in Fiji (43). 307
Mean gray value was converted to optical density with the following equation: OD=Log(Max gray 308 value/Mean gray value). Values for images from five distinct fields of view were averaged to create a single 309 data point for each tumor in each tumor group. CD31 positive microvessels were identified after color 310 deconvolution and analysis of particles greater than 200 pixels with a circularity between 0.00-0.45 in Fiji. 311
Values from 4-10 distinct 10x fields of healthy CD31 stained tissue were analyzed and averaged to create 312 a value for each tumor in each treatment group. Percent TUNEL positive area was determined by using 313
Fiji to measure the TUNEL positive area divided by total tumor area x100 for each tumor. 314 315
Organoid dose response 316
For assays, organoids were seeded as single cells in 40 μL of 33% Matrigel (mouse organoids) or Prostate 317 18 QGel 3D Matrix (NCI-H660 organoids) in 96-well tissue culture plates and cultured for 2 days at 37°C to 318 allow organoid formation. Once formed, organoids were treated with AD80 (at concentrations of ranging 319 from 0.1 μM to 30 μM), or DMSO, with 10 μM Enzalutamide (MedchemExpress) for 72 hours. After 320 treatment, cells were stained with 10 μL ReadyProbes Cell Viability Imaging Kit Blue/Red (Invitrogen) per 321 well for 30 minutes at room temperature and z-stack images of stained cells were taken using an EVOS FL 322
Auto 2 Cell Imaging System (Invitrogen). The percentage of cell death was calculated by identifying the 323 percentage of PI-positive cells per organoid in at least 10 organoids for each treatment condition. 324 325
Statistical Analysis 326
For xenograft tumor volume experiments, means and confidence intervals (CIs) were calculated 327 on the log scale due to skew and reported in terms of geometric means after exponentiation. Geometric 328 mean tumor volumes were compared on the final day by treatment group using a linear regression model adjusted for baseline log tumor volume. When there was a significant overall treatment effect, post-hoc 330 pairwise comparisons of the treatment groups were made with p-values adjusted using the multcomp 331 package in R. All other statistical analyses were performed using GraphPad Prism 7 with the tests indicated 332 in the figure legends. P<0.05 was considered to indicate a statistically significant difference. P values were 333 determined with significance indicated as follows; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 334 335 Acknowledgements 336
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